Drug Patents owned by Cara Therap

1. List of Korsuva drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10793596 CARA THERAP Synthetic peptide amides
Nov, 2027

(4 years from now)

US10017536 CARA THERAP Synthetic peptide amides and dimers thereof
Nov, 2027

(4 years from now)

US8536131 CARA THERAP Synthetic peptide amides and dimers thereof
Nov, 2027

(4 years from now)

US7727963 CARA THERAP Synthetic peptide amides
Nov, 2027

(4 years from now)

US7713937 CARA THERAP Synthetic peptide amides and dimeric forms thereof
Nov, 2027

(4 years from now)

US7402564 CARA THERAP Synthetic peptide amides
Nov, 2027

(4 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10138270 CARA THERAP Synthetic peptide amides
Nov, 2027

(4 years from now)

US9359399 CARA THERAP Synthetic peptide amides
Nov, 2027

(4 years from now)

US9334305 CARA THERAP Synthetic peptide amides and dimers thereof
Nov, 2027

(4 years from now)

US8486894 CARA THERAP Synthetic peptide amides and dimeric forms thereof
Nov, 2027

(4 years from now)

US8236766 CARA THERAP Uses of synthetic peptide amides
Nov, 2027

(4 years from now)

US8217007 CARA THERAP Synthetic peptide amides
Nov, 2027

(4 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Aug 23, 2026

Drugs and Companies using DIFELIKEFALIN ACETATE ingredient

NCE-1 date: 2025-08-23

Market Authorisation Date: 23 August, 2021

Treatment: Treatment of moderate-to-severe pruritus associated with chronic kidney disease (ckd-ap) in adults undergoing hemodialysis (hd)

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

KORSUVA family patents

32

United States

3

Korea, Republic of

3

Japan

3

Canada

2

Israel

2

South Africa

2

Mexico

2

Australia

2

Russia

2

Malaysia

2

China

2

New Zealand

2

European Union

1

Denmark

1

Hong Kong

1

Lithuania

1

Slovenia

1

Hungary

1

Brazil

1

Portugal

1

Cyprus

1

Spain

1

Poland

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic